Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Its platform is built around “off-the-shelf” cell therapies engineered with chimeric antigen receptors (CARs), which are intended to be manufactured from unrelated donors and stored for use on demand. The company’s lead program, prulacabtagene autoleucel (prula-cel, formerly ADI-001), is being advanced for autoimmune disease, while ADI-212 is being developed as a next-generation gene-edited and armored candidate for solid tumors. Adicet’s business is still pre-commercial, so its value depends on successful clinical development, regulatory progress, and the ability to scale manufacturing and financing over time.

7.47

7.47

— Adicet Bio, Inc.
%
Clinical-stage cell therapy candidates0% Investigational allogeneic CAR T-cell product candidates being developed for autoimmune disease and oncology.
Gamma delta T-cell platform0% The underlying donor-derived gamma delta T-cell technology used to create off-the-shelf therapies.
Manufacturing and process development0% Internal GMP cell processing, vector manufacturing, and supporting CDMO-based supply chain activities.
Collaboration and license revenue100% Historical revenue from the Regeneron collaboration and license agreement.

Adicet does not yet sell approved products to commercial end customers; its current “customers” are primarily clinical...

  • Autoimmune disease trial patientsprimary

    Patients enrolled in prula-cel studies for lupus nephritis and systemic lupus erythematosus, where the therapy is intended to reset B-cell activity after a single dose.

  • Oncology trial patientsprimary

    Patients with advanced solid tumors, including metastatic castration-resistant prostate cancer, targeted by ADI-212 in early development.

  • Collaboration partnerssecondary

    Biopharma partners that may license programs, share development costs, or provide non-product revenue, as Regeneron has done historically.

  • Clinical trial sites and investigatorssecondary

    Hospitals and research centers that administer the company’s cell therapy trials and generate the clinical data needed for regulatory filings.

Adicet is headquartered in the United States and conducts key manufacturing and development activities at its Redwood...

  • •United States is the core operating base and headquarters market
  • •Redwood City, California hosts internal GMP cell and vector manufacturing
  • •China exposure comes through Adicet Shanghai and a contractual VIE structure
  • •ADI-212 market opportunity is discussed across the U.S., EU5, China, and Japan
  • •Geographic execution risk is tied to FDA, PRC legal, and future ex-U.S. approvals

Adicet’s strategy is to focus capital on a small number of programs with the highest probability of clinical and...

01
Advance prula-cel in autoimmune diseaseshort-term

This is the lead program and the clearest near-term source of clinical validation for the gamma delta CAR T platform.

02
Progress ADI-212 toward IND and first clinical datashort-term

ADI-212 expands the platform into oncology and could broaden the company’s value proposition if it shows solid-tumor activity.

03
Conserve capital and focus resourcesshort-term

As a clinical-stage company with no product revenue, Adicet must manage burn carefully to avoid financing pressure.

04
Build manufacturing and supply-chain resiliencemedium-term

Cell therapy development depends on reliable donor material, vector production, and GMP execution.

Adicet faces the classic risks of a clinical-stage biotech company: uncertain trial outcomes, regulatory delays, and...

critical

Clinical development failure

The company has no approved products, so value depends on prula-cel and ADI-212 proving safe and effective in humans.

Scope
Lead programs in autoimmune disease and oncology
Materiality
high
high

Financing risk

Adicet expects to need substantial additional capital and has limited revenue sources, making dilution or unfavorable financing possible.

Scope
Operating runway and pipeline execution
Materiality
high
high

Manufacturing and supply-chain risk

Cell therapy production depends on donor material, viral vectors, and GMP execution, any of which can delay trials or raise costs.

Scope
Redwood City facility and CDMO network
Materiality
high
medium

PRC legal and VIE structure risk

The company operates in China through contractual arrangements that may face enforcement or regulatory challenges.

Scope
Adicet Shanghai and Adicet VIE
Materiality
medium
medium

Partner concentration risk

All revenue to date came from the Regeneron collaboration, so termination or non-renewal would remove a key non-dilutive funding source.

Scope
Collaboration and license revenue
Materiality
medium
Collaboration and license revenue recognition
Can create lumpy revenue periods and distort trend analysis
Accrued CDMO and CRO expenses
Affects R&D expense and current liabilities
Stock-based compensation
Affects operating expenses and non-cash burn analysis
Going-concern and liquidity assumptions
Important for assessing financing risk and dilution potential

Aditxt, Inc.

ADTX · Pharmaceutical Preparations

Allogene Therapeutics, Inc.

ALLO · Biological Products, (No Diagnostic Substances)

ABEONA THERAPEUTICS INC.

ABEO · Pharmaceutical Preparations

Jade Biosciences, Inc.

JBIO · Pharmaceutical Preparations

Caribou Biosciences, Inc.

CRBU · Biological Products, (No Diagnostic Substances)

FATE THERAPEUTICS INC

FATE · Biological Products, (No Diagnostic Substances)

: 11/08/2026